Axis-Shield founder sells
A round-up of the biggest director deals today so far.
Chief scientific officer Dr Erling Sundrehagen has sold 100,000 shares in diagnostics firm Axis-Shield at 408p a share. The sale raised £408,000. The share price fell 7p to 401p on the day of the announcement.
Dr Sundrehagen still owns 79,645 shares in Axis-Shield. Back in May, Dr Sundrehagen raised £148,000 by selling 50,000 shares at 296p each.
Dr Sundrehagen has a PhD in immunology and founded Norway-based Axis Biochemicals. Axis merged with Shield Diagnostics to form Axis-Shield in 1999. The company is quoted on the London and Oslo Stock Exchanges.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Scotland-based Axis-Shield published an interim management statement at the end of October 2009. At that time management said that revenues were in line with expectations.
The main area of growth is the Point of Care division. There should be 6,500 Afinion point of care analysers in place by the end of 2009 - that includes 2,500 placed during the year. This is helping to increase sales of the Afinion cartridges and production is becoming more efficient, therby boosting margins. Afinion revenues underpin future growth.
The laboratory and distribution divisions are also performing well. The laboratory division sells diagnostic products direct to laboratories, while the distribution side sells Axis-Shield's point of care products in Switzerland and Germany.
Top Director Buys
TUI Travel (TT.) Director name: Mr William WaggottAmount purchased: 15,715 @ 247.80p Value: £38,942
Panther Securities (PNS) Director name: Mr Simon PetersAmount purchased: 8,000 @ 337.50p Value: £27,000
Gartmore Fledgling Trust (GMF) Director name: Mr Rod BirkettAmount purchased: 4,000 @ 368.00p Value: £14,720
Law Debenture Corp. (LWDB) Director name: Prof. John KayAmount purchased: 5,000 @ 271.70p Value: £13,585
Top Director Sells
Jardine Matheson (Singapore) (JAR) Director name: Mr E P K WeatherallAmount sold: 88,000 @ $29.67 Value: $2,610,731
Jardine Matheson (Singapore) (JAR) Director name: Mr Adam Phillip Charles KeswickAmount sold: 88,000 @ $29.67 Value: $2,610,731
Jardine Matheson (Singapore) (JAR) Director name: Mr Benjamin William KeswickAmount sold: 88,000 @ $29.67 Value: $2,610,731
Jardine Matheson (Singapore) (JAR) Director name: Mr Simon L KeswickAmount sold: 88,000 @ $29.67 Value: $2,610,731
TUI Travel (TT.) Director name: Mr Peter James LongAmount sold: 504,947 @ 243.30p Value: £1,228,536
TUI Travel (TT.) Director name: Mr Johan LundgrenAmount sold: 239,753 @ 243.30p Value: £583,319
TUI Travel (TT.) Director name: Mr Paul BowtellAmount sold: 225,567 @ 243.30p Value: £548,805
TUI Travel (TT.) Director name: Mr William WaggottAmount sold: 187,363 @ 243.30p Value: £455,854
Axis-Shield (ASD) Director name: Mr E SundrehagenAmount sold: 100,000 @ 408.00p Value: £408,000
Jardine Matheson (Singapore) (JAR) Director name: Mr Simon L KeswickAmount sold: 10,000 @ $29.74 Value: $297,440
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Spot the Dog: £67bn in underperforming funds revealed
Around 137 funds consistently underperformed their benchmark, BestInvest's Spot the Dog report finds. Which funds are in the dog house?
By Katie Williams Published
-
What does a BP and Shell merger mean for the UK oil industry?
BP’s struggles have made it vulnerable to a takeover. Could it merge with Shell to create a British behemoth?
By Dr Matthew Partridge Published